Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Merck to Begin Arbitration With J & J

By Drug Discovery Trends Editor | September 8, 2010

TRENTON, N.J. (AP) – Drugmaker Merck & Co. said that arbitration will begin in late September in its dispute with Johnson & Johnson over revenue from two blockbuster drugs for rheumatoid arthritis and other immune disorders.

The dispute arose when Merck bought Schering-Plough Corp., which has shared billions in revenue with J&J from Remicade and a successor drug, Simponi.

Merck structured its purchase of Schering-Plough as a reverse merger, meaning that Schering-Plough technically was the surviving corporation. That was an attempt to block change-of-control provisions in Schering’s contract with J&J.

Johnson & Johnson has argued that those provisions are in force and that it is entitled to Schering-Plough’s share of revenue from the drugs – roughly $2 billion a year – plus damages.

In May, J&J’s biotech subsidiary Centocor informed Merck it was initiating an arbitration proceeding, as investors had expected. Both companies have kept mum about the dispute, but Merck’s general counsel, Bruce Kuhlik, told analysts on a July 30 conference call he hoped to provide additional information soon.

In a filing with the Securities and Exchange Commission Tuesday, Merck said that the arbitration case would be heard in New York City by a panel of three former federal judges, whom it did not identify. The hearing is expected to last up to 12 business days and the panel is then expected to make a decision within 20 business days after that.

“We continue to believe very strongly that we’ve structured this transaction in a way that’s appropriate for the Remicade distribution agreement,” Kuhlik told analysts in July.

Merck wrote in the SEC filing that it is being represented by attorneys William Ohlemeyer, Scott Vernick and David Boies. Boies is the high-profile lawyer who represented former Vice President Al Gore in litigation over the results of the 2000 presidential election and was special counsel for the Justice Department in its antitrust suit against Microsoft.

Johnson & Johnson is being represented by the firm Patterson Belknap Webb & Tyler LLP, Merck reported Tuesday. J&J officials did not return a call seeking comment.

Merck noted the two companies could decide to resolve the dispute privately – an outcome some analysts have predicted – but that could mean a change in how the companies split proceeds from the drugs. J&J already gets the larger share, posting $4.3 billion in sales from Remicade alone last year; it did not report separate sales from then-new Simponi.

Merck bought Schering-Plough for $41 billion last November, one of several major pharmaceutical mergers in 2009. The deal was part of Merck’s strategy to diversify by adding Schering’s businesses in biologic drugs, veterinary medicine and consumer health products, plus several promising experimental drugs Schering-Plough has been testing.

Date: September 7, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50